Arbutus Biopharma (ABUS)
(Delayed Data from NSDQ)
$3.47 USD
+0.06 (1.76%)
Updated Aug 6, 2025 04:00 PM ET
After-Market: $3.46 -0.01 (-0.29%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ABUS 3.47 +0.06(1.76%)
Will ABUS be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ABUS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ABUS
Arbutus Biopharma (ABUS) Beats Q2 Earnings and Revenue Estimates
Arbutus Biopharma (ABUS) Reports Q1 Loss, Tops Revenue Estimates
ABUS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Fate Therapeutics (FATE) Reports Q1 Loss, Tops Revenue Estimates
Is Editas Medicine (EDIT) Stock Outpacing Its Medical Peers This Year?
Is Boston Scientific (BSX) Stock Outpacing Its Medical Peers This Year?
Other News for ABUS
Arbutus Biopharma Corp Reports Q2 2025 Earnings: EPS of $0.01 and Revenue of $10. ...
Arbutus Biopharma GAAP EPS of $0.01 beats by $0.06, revenue of $10.74M
Arbutus Reports Second Quarter 2025 Financial Results and Provides Corporate Update | ABUS ...
Arbutus Biopharma reports Q2 EPS 1c vs (11c) last year
Arbutus Biopharma Ends Partnership with Qilu Pharmaceutical